0001140361-18-030196.txt : 20180627 0001140361-18-030196.hdr.sgml : 20180627 20180627185803 ACCESSION NUMBER: 0001140361-18-030196 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180626 FILED AS OF DATE: 20180627 DATE AS OF CHANGE: 20180627 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: THOMPSON PHILLANDAS T. CENTRAL INDEX KEY: 0001661781 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 18922838 MAIL ADDRESS: STREET 1: 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 4 1 doc1.xml FORM 4 X0306 4 2018-06-26 0 0001012477 AVADEL PHARMACEUTICALS PLC AVDL 0001661781 THOMPSON PHILLANDAS T. BLOCK 10-1, BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN DUBLIN L2 15 IRELAND 0 1 0 0 See Remarks ADSs 2018-06-26 4 P 0 10000 5.77 A 91000 D Stock Option (right to buy) 7.36 2023-12-12 ADSs 100000 100000 D Stock Option (right to buy) 16.3 2024-12-11 ADSs 95000 95000 D Stock Option (right to buy) 14.35 2025-12-10 ADSs 100000 100000 D Stock Option (right to buy) 10.4 2026-12-14 ADSs 100000 100000 D Stock Option (right to buy) 8.95 2027-12-12 ADSs 80000 80000 D The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Includes (a) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the 4th anniversary of the grant date; (b) 20,000 restricted ADSs granted under the "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the 2nd anniversary of the grant date; (c) 18,000 restricted ADSs granted under the "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the 2nd anniversary of the grant date; and (d) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary). Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2013 grant date. Options become exercisable as to 23,750 ADSs on each of the first four anniversaries after the 12/11/2014 grant date. Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date. Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date. Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date. Sr. VP, General Counsel and Corporate Secretary. /s/ Phillandas T. Thompson 2018-06-27